One of the goals of molecular pharmacology is to understand the machinery that converts information about the presence of a chemical (binding) to a functional consequence. Agonists are drugs which bind to their molecular targets and cause conformational changes underlying activation of the target. Inevitably, therefore, it can be difficult to disentangle the affinity of the agonist for the target from its efficacy in producing the ensuing conformational change. Efficacy depends on two factors: the intrinsic equilibrium between active and inactive states in the absence of agonist, and the energy contributed by the agonist due to the relative affinities of agonist for the active and inactive states. These difficulties are particularly frustrating when the goal is to determine the role(s) that particular residues in a target protein have in shaping the overall efficacy of a drug: how is it possible to unambiguously distinguish a role in determining intrinsic efficacy from one in determining relative affinity? This perspective highlights a research article in this issue (p.___) which demonstrates a quantitative approach to the resolution of this problem in the case of activation of the muscle nicotinic receptor. This elegant (if demanding) approach involves determining, separately, the consequences of specific mutations on gating in the unliganded and liganded states.
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The evolution of our thinking about how drug effects are mediated received a strong impetus when Langley (Langley, 1905) proposed that nicotine combines with a specific receptive substance in striated muscle (see Figure 1A ) and shortly afterwards Hill (Hill, 1909) derived a simple binding equation. However, further advances in understanding agonist activity were slow in coming. In 1956 Stephenson (Stephenson, 1956) introduced the concept that "affinity," the binding interaction between drug and target, and "efficacy," the ability of the drug to produce an effect, are separable. del Castillo and Katz (del Castillo and Katz, 1957) were the first to propose a specific kinetic scheme with separate steps for binding and activation ( Figure   1B ), again for the muscle nicotinic receptor to explain the nature of partial agonists. Subsequent work demonstrated that almost all of the active nicotinic receptors had 2 bound agonist molecules. The advent of high resolution single channel recordings then provided evidence that the receptors could be active, albeit rarely, when only a single agonist was bound (Colquhoun and Sakmann, 1985) , or even in the absence of agonist (Jackson, 1984) . At present the core activation scheme for the nicotinic receptor shows 6 major states for the receptor: open-or closed-channel conformations each with 3 degrees of ligation ( Figure 1C ). Other long-lived states have been identified, most prominently the desensitized state, but they can be separated out in single channel recordings so that this core activation process can be studied. It is also clear that the transition between closed and open states proceeds through a series of short-lived intermediate states (Auerbach, 2010) , some of which have been detected in high resolution recordings (Lape et al., 2008; Mukhtasimova et al., 2009) .
The scheme in Figure 1C is a two-conformation, concerted transition mechanism MOL #70102 This article has not been copyedited and formatted. The final version may differ from this version. (Changeux and Podleski, 1968; Monod et al., 1965; Wyman and Allen, 1951) The research in the article by Purohit and Auerbach (page ___) is on the muscle nicotinic receptor. A long series of studies has provided a strong quantitative picture of activation, and the analysis of a myriad of mutated residues (in conjunction with structural information) has given insights into the timing of conformational changes in different regions, the interactions among amino-acid side chains, and the basis for interactions between an agonist and the receptor. What the authors have done to extend this knowledge is to dissect the contribution of particular residues to two aspects of agonist efficacy: the relative binding affinities for the closed-and open-channel states, and the intrinsic efficacy for channel opening. The approach relies on the kinetic framework shown in Figure 1C .
MOL #70102
This article has not been copyedited and formatted. The final version may differ from this version. The agonist-binding site in the nicotinic receptor is formed at the interface between two subunits (see Figure 1 of Purohit and Auerbach) . The α subunit contributes 3 "loops" (the A, B
and C loops) and the adjacent δ or ε subunit contributes 3 more. The α subunit B loop contains a critical tryptophan residue (W149) which is involved in agonist binding, and has 2 glycine residues, one at either end (G147 & G153). The question the authors address is whether flexibility of the loop, associated with presence of the glycine "hinges" at the ends, is required for normal function.
Purohit and Auerbach measured the opening equilibrium for the diliganded receptor (E 2 ) and for the unliganded receptor (E 0 ), using single channel recordings. E 2 is (relatively) straightforward: the channel opening rate is measured at a saturating concentration of agonist, the closing rate at a low concentration, and the ratio computed. Measuring E 0 is more complicated, because the value is extremely low (for wild-type receptors it is about 5x10 -7 ), and so events are too rare to unambiguously characterize. (Values for E 0 have been estimated for other channels and also are quite small; e.g. for the GABA A receptor ~10 -5 (Chang and Weiss, 1999) and for the BK potassium channel ~10 -7 (Horrigan and Aldrich, 2002) .) Purohit and Auerbach utilized a subunit which contained a set of mutations which greatly increase the occurrence of unliganded openings as the base construct. The effect of the additional mutation under study was then compared to the base parameters. This approach relies on a demonstration that the effects of the background mutations are independent (energetic contributions to activation are additive) among themselves and with the test mutation (Jha and Auerbach, 2010; Purohit and Auerbach, 2009; Purohit and Auerbach, 2010) .
This article has not been copyedited and formatted. The final version may differ from this version. What is the answer? Mutations to the two glycines have opposite effects on the efficacy of gating for diliganded receptors, by affecting different parameters (see Figure 2 ). Mutations to G147 decrease E 0 , by decreasing the opening rate and increasing the closing rate. In contrast, mutations to G153 increase E 0 , by increasing the opening rate and somewhat slowing the closing rate. The consequences for the relative affinities are different. In this case, mutations to G147 greatly decrease λ , while mutations to G153 decrease λ only slightly. The overall effect is that the mutations to G147 greatly decrease the efficacy of gating for diliganded receptors (E 2 decreases more than 1000-fold) while mutations to G153 increase E 2 by 10-to 60-fold. The authors also measured the affinity for the resting receptor for selected mutations. The affinity was decreased by the mutation G147S (K D increased), and increased by 3 mutations at G153.
Clearly, these "hinges" are significant determinants of overall receptor function. Flexibility at G147 seems to be critical for positioning residues in the binding site for optimal interaction with the agonist, both for the resting receptor and even more so for the open-channel receptor. In contrast, flexibility at G153 seems to be more important for governing the efficacy of gating. As the authors put it, G147 is an "activation hinge" while G153 is a "deactivation hinge."
Mutations to the binding residue, W149, consistently reduce λ (Figure 2) 
This article has not been copyedited and formatted. The final version may differ from this version. 8 Loop B has not been previously studied in terms of conformational flexibility. Attention has been focused on Loop C, as X-ray crystallographic studies of the related ACh-binding protein indicated that loop C closes down on bound agonists (Celie et al., 2004) , and studies of mutated subunits support the idea that this closure is functionally important (Mukhtasimova et al., 2009) . The present work demonstrates that conformational flexibility in other parts of the binding site is critical for normal function of the receptor.
It is interesting to note that much larger changes occurred in the rate for entering the diliganded open state than in leaving the diliganded open state. This seems perhaps unintuitive,
given that the high-affinity (open) conformation is expected to be stabilized by binding. The explanation likely lies in the rapid, largely unresolved transitions between states that the receptor makes as it opens (Auerbach, 2010) . Perhaps the stabilizing energy contributed by agonist binding to the high-affinity form of the receptor increases the likelihood that the receptor will be in states further along the opening transition pathway, but before the final step for opening. This would agree with the observations that activation by agonists with different efficacies results in similar rates for leaving the diliganded open state, but very different rates for entering it.
Previous workers have also concluded that the major determinants of efficacy lie in transitions preceeding actual channel opening (Lape et al., 2008; Mukhtasimova et al., 2009) . One physical interpretation is that the increase in affinity reflects closure of the agonist-binding site (Mukhtasimova et al., 2009) . In this case, it seems that flexibility in Loop B is critical, as well as movement of Loop C.
This work sets a standard for examining structure-activity relationships for activation of
This article has not been copyedited and formatted. The final version may differ from this version. proteins by drugs. It builds on a broad data-base and requires the precision of single-protein kinetics, as well as the demonstration that a particular kinetic scheme is appropriate for analysis.
The power of this approach is also a limitation: it requires the quantitative validation of the kinetic scheme applied and extremely high-quality data with high time resolution. The lessons learned will be valuable in interpreting data from other, less complete studies and will definitely be applicable to understanding the other members of the nicotinic receptor gene family. Figure 1 . Kinetic models for agonist activation of the nicotinic receptor. Panel A shows the initial concept that an agonist (A) binds to a receptor (R), to produce an active complex (AR*; Langley, 1905; Hill, 1909) . state (λ = K D /J D >> 1). The second is the intrinsic opening equilibrium for the unliganded receptor (E 0 ). The opening equilibrium for the doubly-liganded receptor (A 2 R ↔ A 2 R*; E 2 = λ 2 E 0 ) is much larger than for the unliganded receptor. This article has not been copyedited and formatted. The final version may differ from this version. 
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